Urine Microalbumin (ACR)
For informational purposes only — not medical advice. Always consult a qualified healthcare provider before making changes to your health regimen. Full disclaimer →
- ACR detects kidney damage years before eGFR falls — at a stage when intervention can stop or reverse it. Conventional kidney function testing (serum creatinine, eGFR) only declines when substantial nephron loss has occurred. The ACR identifies glomerular filtration barrier disruption when it is still a functional impairment, before irreversible structural damage accumulates. In people with diabetes or hypertension, microalbuminuria typically precedes eGFR decline by 5–10 years — a window during which optimized blood pressure control, renin-angiotensin system blockade, and glycemic management can normalize or stabilize ACR and preserve kidney function.
- Microalbuminuria is a cardiovascular risk marker independent of its kidney implications. The association between ACR and cardiovascular events holds across people with and without diabetes, across a broad range of ages, and after adjustment for conventional cardiovascular risk factors. This is not coincidental — glomerular endothelial damage is a manifestation of systemic endothelial dysfunction, the same process that drives atherosclerosis. A person with elevated ACR and no other apparent cardiovascular risk factors deserves a more thorough cardiovascular risk assessment than their LDL-C or blood pressure alone would suggest.
- ACR should be a routine component of longevity monitoring for anyone with hypertension, metabolic syndrome, diabetes, or a family history of kidney disease. The American Diabetes Association recommends annual ACR screening for all people with diabetes. For people with hypertension — one of the most prevalent and undertreated conditions globally — ACR identifies subclinical target organ damage that substantially changes the risk picture. People with metabolic syndrome (insulin resistance + elevated triglycerides + low HDL + elevated glucose + hypertension) have markedly elevated rates of microalbuminuria independent of overt diabetes.
- Elevated ACR is a modifiable risk factor — the interventions that lower ACR are the same ones that reduce cardiovascular mortality. Angiotensin-converting enzyme (ACE) inhibitors and angiotensin receptor blockers (ARBs) reduce intraglomerular pressure and have specific nephroprotective effects beyond blood pressure lowering; they are the first-line agents for microalbuminuria in people with hypertension or diabetes. Blood pressure control below 130/80 mmHg independently reduces ACR. SGLT2 inhibitors (sodium-glucose cotransporter 2 inhibitors, originally developed for diabetes) reduce ACR dramatically and have proven benefit in reducing cardiovascular and kidney outcomes — including in people without diabetes. Weight loss, exercise, and dietary sodium reduction also reduce ACR.
- Testing requires a random urine sample — no fasting, no 24-hour collection — making it one of the most logistically simple tests in longevity panels. A random urine sample collected at any time of day is sufficient for ACR measurement. Creatinine normalization adjusts for the wide variation in urine concentration across specimens and times of day, making results comparable. The one caveat: avoid testing during heavy exercise, active infection, fever, or menstruation, all of which transiently elevate urinary albumin and can produce false positive results.
The Kidney Damage Signal That Arrives Decades Early
The trajectory of kidney disease has a characteristic pattern that makes early detection enormously valuable. Kidney function begins declining in response to hypertension, hyperglycemia, and other vascular insults years to decades before conventional markers — serum creatinine, eGFR — show any change. This is because the kidney has substantial reserve capacity: even after losing 30–40% of nephron function, eGFR may still appear normal because remaining nephrons compensate by hyperfiltrating.
The albumin-to-creatinine ratio detects damage at a far earlier stage. The glomerular filtration barrier — the specialized structure that prevents protein from crossing into the urine — is disrupted by the same hemodynamic and metabolic stresses that will eventually damage kidney function. Elevated intraglomerular pressure from systemic hypertension, direct glomerular damage from advanced glycation end-products in insulin resistance, and inflammatory cytokine effects on the endothelium all produce glomerular barrier disruption measurable as microalbuminuria years before any eGFR decline.
This window — elevated ACR with preserved eGFR — is the optimal intervention point. The kidney has not yet lost substantial nephron mass, and the damage is largely functional and potentially reversible with appropriate treatment. Multiple trials in diabetic and hypertensive populations have shown that ACE inhibitors and ARBs can normalize microalbuminuria in a substantial proportion of patients and significantly slow or prevent progression to overt proteinuria and kidney function decline.
ACR as a Systemic Vascular Health Marker
The association between microalbuminuria and cardiovascular risk extends well beyond the kidney. The glomerular endothelium and systemic vascular endothelium share similar exposure to hemodynamic stress, metabolic insults, and inflammatory signals. Glomerular barrier dysfunction is a proxy for generalized endothelial dysfunction — the leaky filtration barrier reflects the same vascular biology that drives atherosclerosis and cardiovascular events.
This is why the HOPE trial found that microalbuminuria was an independent predictor of cardiovascular events in high-risk adults without prior kidney disease — and why multiple meta-analyses confirm that ACR predicts cardiovascular mortality across populations with and without diabetes. The ACR adds cardiovascular risk information beyond what conventional risk factors capture. 1
| ACR (mg/g) | Category | Longevity Interpretation |
|---|---|---|
| < 10 mg/g | Longevity optimal | Minimal glomerular and vascular risk signal |
| 10–29 mg/g | High-normal | Gradient of risk; trend over time matters |
| 30–300 mg/g | Microalbuminuria | Significant kidney and cardiovascular risk; intervene |
| > 300 mg/g | Macroalbuminuria | Advanced glomerular damage; clinical management |
| Range Type | Value (mg/g (mg albumin per g creatinine)) | Notes |
|---|---|---|
| Standard Clinical Range | Normal: < 30 mg/g (mg albumin per g creatinine) · Microalbuminuria: 30–300 mg/g · Macroalbuminuria: > 300 mg/g | Designed to identify disease risk — not longevity optimisation. |
| Longevity-Optimal Target | < 10 mg/g |
Associated with reduced all-cause mortality and extended healthspan.
The standard clinical threshold for microalbuminuria (30 mg/g) was derived primarily from studies in diabetic populations to predict progression to overt nephropathy. In the general population and in longevity contexts, the dose-response relationship between ACR and cardiovascular and all-cause mortality risk begins below this threshold — multiple cohort studies find that ACR in the 10–29 mg/g range ('high-normal') is associated with higher risk than ACR below 10 mg/g. The longevity-optimal target of < 10 mg/g reflects this continuous risk gradient. A single elevated ACR should be confirmed on two additional samples over 3–6 months, since transient elevation can occur with heavy exercise, fever, menstruation, urinary tract infection, or significant physiological stress — all of which should be absent during confirmatory testing.
|
Already have your results? See what your Urine Microalbumin (ACR) and other markers reveal about your longevity in 60 seconds.
Analyze My Labs →Affiliate disclosure: we may earn a commission if you purchase through these links at no extra cost to you.
My ACR is 18 mg/g — my doctor says that's normal. Should I be concerned?
Your doctor is technically correct that 18 mg/g falls below the clinical threshold for microalbuminuria (30 mg/g) and would typically be reported as normal. From a longevity perspective, ACR in the 10–29 mg/g range sits in a gradient of cardiovascular and kidney risk that begins below the clinical threshold. Multiple large cohort studies — including analyses from NHANES and the Chronic Kidney Disease Prognosis Consortium — have found that ACR values as low as 10–15 mg/g are associated with higher rates of cardiovascular events and mortality compared to values below 10 mg/g, even in people without diabetes or hypertension. Whether 18 mg/g is personally concerning for you depends on your overall risk context: someone with otherwise excellent cardiometabolic markers, no hypertension, no diabetes, and no family history of kidney disease has a different interpretation than someone with metabolic syndrome and elevated ApoB. That said, a value trending upward over successive annual measurements warrants attention regardless of absolute level.
What should I not do before a urine ACR test?
Avoid intense exercise in the 24–48 hours before testing — strenuous exercise transiently increases glomerular filtration pressure and can elevate urinary albumin substantially, producing a false positive. Also avoid testing during active fever, urinary tract infection, or menstruation. Significant physiological stress (recent surgery, trauma, acute illness) will also elevate ACR acutely. Standard fasting is not required — this is a urine test and food intake doesn't directly affect urine albumin. First morning urine is sometimes preferred as it has more consistent concentration, but a random mid-day sample with creatinine normalization is acceptable. The most important preparation is simply avoiding the confounders listed above — a single elevated ACR under any of these conditions should be retested under stable conditions before clinical decisions are made.
How does ACR relate to eGFR in staging kidney disease?
The current CKD (chronic kidney disease) staging system from the Kidney Disease Improving Global Outcomes (KDIGO) guidelines uses both eGFR and ACR together — this dual staging recognizes that both filtration rate and albuminuria are independent predictors of kidney disease progression and cardiovascular risk. A person with eGFR 65 mL/min/1.73m² and ACR 40 mg/g has a higher risk of progression and cardiovascular events than a person with the same eGFR and ACR 8 mg/g. This dual staging also captures the important subgroup with preserved eGFR but elevated ACR — people who have glomerular damage without yet-measurable GFR decline. In the context of longevity monitoring, tracking both eGFR and ACR annually provides more complete kidney health information than either alone. ACR should be added to any panel that includes serum creatinine and eGFR.
Can ACR improve with lifestyle changes alone, without medication?
Yes — mildly elevated ACR (30–100 mg/g) in people without severe hypertension or diabetes often responds meaningfully to lifestyle intervention. Blood pressure reduction is the most powerful modifiable driver of ACR — each 5 mmHg reduction in systolic blood pressure produces measurable ACR improvement. Weight loss reduces intraglomerular hypertension and has documented ACR-lowering effects in people with metabolic syndrome and obesity. Dietary sodium restriction reduces blood pressure and has direct kidney protective effects on glomerular filtration pressure. Exercise improves vascular function and reduces blood pressure. Smoking cessation significantly reduces microalbuminuria. For people with ACR in the 30–100 mg/g range and no compelling indication for RAS blockade, a 6–12 month trial of intensive lifestyle modification is a reasonable first step before considering pharmacological intervention, with repeat ACR measurement to confirm response.